Perceptions, experiences, and motivation of COVID-19 vaccine trial participants in South Africa: a qualitative study.

Autor: Nkosi T; School of Public Health, University of the Western Cape, Bellville, Cape Town, South Africa. Thandeka.Nkosi@hiv-research.org.za.; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa. Thandeka.Nkosi@hiv-research.org.za., Mulopo C; School of Public Health, University of the Western Cape, Bellville, Cape Town, South Africa., Schmidt BM; School of Public Health, University of the Western Cape, Bellville, Cape Town, South Africa.; Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.

Publikováno v: Research integrity and peer review [Res Integr Peer Rev] 2024 Jul 29; Vol. 9 (1), pp. 8. Date of Electronic Publication: 2024 Jul 29.

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD81 T cells into B-cell follicles during HIV-1 infection

Autor: Ogunshola, F., Smidt, W., Naidoo, A., Nkosi, T., Ngubane, T., Khaba, T., Baiyegunhi, O., Mahlobo, B., Rasehlo, S., Ngema, N., Jajbhay, I., Dong, K., Ramsuran, V., Pansegrouw, J., Ndung'u, T., Walker, B., de Oliveria, T., Ndhlovu, Z.

Publikováno v: Blood Adv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1874::285d537a5544544ac8772fc863f33c66
https://hdl.handle.net/21.11116/0000-000A-6F85-421.11116/0000-000A-6F87-2

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CD8 lymphocytes mitigate HIV-1 persistence in lymph node follicular helper T cells during hyperacute-treated infection.

Autor: Baiyegunhi OO; Africa Health Research Institute (AHRI), Durban, South Africa.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa., Mann J; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa., Khaba T; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa., Nkosi T; Africa Health Research Institute (AHRI), Durban, South Africa., Mbatha A; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa., Ogunshola F; Africa Health Research Institute (AHRI), Durban, South Africa.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA., Chasara C; Africa Health Research Institute (AHRI), Durban, South Africa., Ismail N; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa., Ngubane T; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa., Jajbhay I; Prince Mshiyeni Memorial Hospital, Durban, South Africa., Pansegrouw J; Prince Mshiyeni Memorial Hospital, Durban, South Africa., Dong KL; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA., Walker BD; Africa Health Research Institute (AHRI), Durban, South Africa.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.; Institute for Medical Sciences and Engineering and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA.; Department of Immunology, Harvard Medical School, Boston, MA, USA., Ndung'u T; Africa Health Research Institute (AHRI), Durban, South Africa.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.; Max Planck Institute for Infection Biology, Berlin, Germany.; Division of Infection and Immunity, University College London, London, UK., Ndhlovu ZM; Africa Health Research Institute (AHRI), Durban, South Africa. zndhlovu@mgh.harvard.edu.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. zndhlovu@mgh.harvard.edu.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA. zndhlovu@mgh.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2022 Jul 12; Vol. 13 (1), pp. 4041. Date of Electronic Publication: 2022 Jul 12.

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8+ T cells into B-cell follicles during HIV-1 infection.

Autor: Ogunshola FJ; Africa Health Research Institute, Durban, South Africa.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA., Smidt W; Africa Health Research Institute, Durban, South Africa.; KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa., Naidoo AF; HIV Vaccine Trial Network, Cape Town, South Africa., Nkosi T; Africa Health Research Institute, Durban, South Africa.; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa., Ngubane T; Prince Mshiyeni Memorial Hospital, Durban, South Africa., Khaba T; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa., Baiyegunhi OO; Africa Health Research Institute, Durban, South Africa.; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa., Mahlobo B; Africa Health Research Institute, Durban, South Africa., Rasehlo S; Africa Health Research Institute, Durban, South Africa., Ngema N; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa., Jajbhay I; Prince Mshiyeni Memorial Hospital, Durban, South Africa., Dong KL; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA., Ramsuran V; KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa., Pansegrouw J; Prince Mshiyeni Memorial Hospital, Durban, South Africa., Ndung'u T; Africa Health Research Institute, Durban, South Africa.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA.; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.; Max Planck Institute for Infection Biology, Berlin, Germany., Walker BD; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA.; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.; Howard Hughes Medical Institute, Chevy Chase, MD; and.; Institute for Medical Engineering and Sciences and Department of Biology, Massachusetts Institute of Technology, Cambridge MA., Oliveria T; KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa., Ndhlovu ZM; Africa Health Research Institute, Durban, South Africa.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA.; Prince Mshiyeni Memorial Hospital, Durban, South Africa.

Publikováno v: Blood advances [Blood Adv] 2022 Mar 22; Vol. 6 (6), pp. 1904-1916.